Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) EBITDA Margin (2025)

Centessa Pharmaceuticals has reported EBITDA Margin over the past 1 years, most recently at 188.49% for Q1 2025.

  • Quarterly EBITDA Margin changed N/A to 188.49% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 1326.87% through Dec 2025, changed N/A year-over-year, with the annual reading at 1326.87% for FY2025, N/A changed from the prior year.
  • EBITDA Margin was 188.49% for Q1 2025 at Centessa Pharmaceuticals.
  • Over five years, EBITDA Margin peaked at 188.49% in Q1 2025 and troughed at 188.49% in Q1 2025.